My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...

Nancy Pelosi just made Tempus AI (TEM) the stock of the moment. The former Speaker of the House quietly purchased 50 call ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Shares of Tempus AI (TEM) are rising 5% in pre-market trading after surging 13% yesterday. The healthcare-focused AI stock ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

Shares of Tempus AI rose by 13.36 percent on Thursday to close at $83.75 apiece as investors cheered the company’s ...

Tempus AI shares soared to an all-time high Thursday as the tech firm announced a collaboration with the nonprofit Institute ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).